Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Benefits for OTC-Like Ethical Drugs to Be Reviewed in 4 to 5 Years
July 30, 2007
-
ARCHIVE 11 Generic Products (6 APIs) to Be Listed in November
July 30, 2007
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
-
ARCHIVE NPhA to Further Promote Use of Generics
July 30, 2007
-
ARCHIVE OPINION/Once in a Lifetime
July 30, 2007
-
ARCHIVE Comtan Stabilizes Levodopa Concentrations: Novartis Seminar
July 23, 2007
-
ARCHIVE MTPC Aims to Successively Launch Global Products, Stably Supply High-Quality Essential Drugs: Mr Hayama
July 23, 2007
-
ARCHIVE Number of Candidate Compounds Show Promise for NSCLC: Pfizer
July 23, 2007
-
ARCHIVE Daiichi Sankyo Obtains License on Denosumab from Amgen
July 23, 2007
-
ARCHIVE Otsuka, GW Pharmaceuticals Sign Joint Research Agreement
July 23, 2007
-
ARCHIVE Wyeth Japan Committed to Catching Up with the Rest of the World
July 23, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 23, 2007
-
COMMENTARY COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
-
ARCHIVE Exelon Patch Approved for Alzheimer's Disease: Novartis
July 23, 2007
-
ARCHIVE Price Agreement Rate Rose to 92.4% as of End of March
July 23, 2007
-
ARCHIVE R&D NEWS IN BRIEF
July 23, 2007
-
ARCHIVE Promote Multinational Clinical Trials to Eliminate Drug Lag: Study Group
July 23, 2007
-
ARCHIVE NEW PRODUCTS
July 23, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…